Develops RNAi drugs for rare genetic diseases.
Jun 2026Revenue $669M/yrExpenses $896M/yr
No trend
Figures by year
When will Arrowhead Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $669M and expenses $896M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Sep 2025 | $829M | $731M | $98.3M |
| Sep 2024 | $3.55M | $605M | −$601M |
| Sep 2023 | $241M | $446M | −$205M |
| Sep 2022 | $243M | $422M | −$179M |
| Sep 2021 | $138M | $287M | −$149M |
| Sep 2020 | $88.0M | $181M | −$93.2M |
| Sep 2019 | $169M | $108M | $61.2M |
| Sep 2018 | $16.1M | $72.1M | −$55.9M |
| Sep 2017 | $31.4M | $68.4M | −$37.0M |
| Sep 2016 | $158K | $81.9M | −$81.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.